OrthoTrophix Presents Data on TPX-100, Meniscal Pathology and Structural Progression in Knee Osteoarthritis
Two studies at ACR Convergence 2026 suggest potential structural effects of TPX-100 and identify patients who may benefit most. FOSTER CITY, Calif., Nov. 9, 2026 /PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced data from two posters at ACR...
Covered in this story
Call it yourself
No calls on $ACR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Acres Commercial Realty Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.